Abstract
ABSTRACT Academic scientists and research institutes are increasingly being evaluated using digital metrics, from bibliometrics to patent counts. These metrics are often framed, by science policy analysts, economists of science as well as funding agencies, as objective and universal proxies for scientific worth, potential, and productivity. In biomedical science, where there is stiff competition for grants from the National Institutes of Health (NIH), metrics are sold as a less arbitrary way to allocate funds, yet the funding context in which metrics are applied is not critically examined. Success by the metrics is in fact inextricably linked to the distribution of NIH funds, and from the 1980s to the 2000s, NIH funding has been marked by high inequality (elite investigators and institutes get the lion’s share of resources) and decreased mobility (those who start at the bottom are less likely to rise to the upper ranks). Elite investigators and institutes currently produce the bulk of prestigious publications, citations, and patents that commonly used metrics valorise. Metrics-based evaluation therefore reproduces, and potentially amplifies, existing inequalities in academic science and rich-get-richer effects.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.